We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Global Lateral Flow Assays Market to Reach USD 13.85 Billion by 2027 Due to Benefits of Rapid Tests and Growing Demand for POC Testing

By LabMedica International staff writers
Posted on 20 May 2021
Print article
Illustration
Illustration
The global lateral flow assays market is expected to grow at a CAGR of 8.8% from 2020 to 2027 to reach USD 13.85 billion by 2027, driven mainly by the benefits of LFA-based rapid tests over laboratory testing and growing demand for point-of-care testing.

These are the latest findings of Meticulous Research (Redding, CA, USA), a market intelligence provider.

Lateral flow assays are devices used to confirm the presence or absence of a target analyte without the need for lab equipment. These devices are widely used in hospitals and clinical laboratories for the qualitative and quantitative detection of specific antigens and antibodies. It is a simple and low-cost technology used in qualitative and quantitative detection of pathogens or biomarkers in humans or animals, or contaminants or toxic elements in water supplies, foodstuffs, or animal feeds.

The growth of the overall lateral flow assays market is mainly attributed to the benefits of LFA-based rapid tests over laboratory testing, increasing usage of home-based lateral flow assay kits, growing demand for point-of-care testing, increasing prevalence of chronic & infectious diseases, and growing acceptance of smart devices. In addition, evolving applications of lateral flow assays and rising demand for lateral flow assays in the food & beverage industry offer significant growth opportunities for players operating in the lateral flow assays market. On the other hand, the reluctance towards changing existing diagnostic practices and the development of multiplexing assays are some of the factors challenging the growth of this market to a certain extent. Also, variance in lateral flow assay test results and stringent regulations are expected to hinder the growth of this market.

Based on product, the kits & reagents segment accounted for the largest share of the overall lateral flow assays market in 2020, led by the higher adoption rate of kits & reagents, increasing use of home-based lateral flow assay devices, and growing demand for point-of-care testing. On the basis of technique, the sandwich assays segment accounted for the largest share of the overall lateral flow assays market in 2020, due to the wide application of sandwich assays in various medical testing settings and their advantages, such as higher sensitivity and specificity for larger analytes.

Based on application, the clinical testing segment accounted for the largest share of the overall lateral flow assays market in 2020, on the back of increasing healthcare expenditure, rising initiatives towards health awareness, growing awareness about clinical testing, and increasing spread of various chronic and infectious diseases. Based on end user, diagnostic laboratories accounted for the largest share of the overall lateral flow assays market in 2020, on account of increasing adoption of lateral flow assays due to their benefits over conventional laboratory tests, increasing use of PoC tests, growing hospital admissions, and rapid growth in demand for lateral flow tests during COVID-19. Geographically, North America accounted for the largest share of the global lateral flow assays market in 2020, followed by Europe and Asia-Pacific. The increasing prevalence of chronic and infectious diseases, rising geriatric population, growing demand for point-of-care testing facilities, and presence of key players in the region are driving the growth of the North American lateral flow assays market.

Related Links:
Meticulous Research

New
Gold Supplier
SARS-CoV-2 Multiplex Real-Time RT-PCR Assay
GSD NovaPrime Plus SARS-CoV-2
New
Automated RNA Extraction & PCR Setup
Omnia LH 75 Pro
New
Gold Supplier
Fluorimetric Immunoassay Analyzer
Confiscope F20
New
Urea Breath Test System for H. Pylori
BreathID Hp Lab

Print article

Channels

Pathology

view channel

Certest Offers Real-Time PCR Assays for Fast Detection of MDR Bacterial Infections

CerTest Biotec (Zaragoza, Spain) has joined the fight against multidrug resistant strains (MDR) bacterial infections by developing real-time PCR assays for the fast detection of genes or punctual mutations that confer resistance to antibiotics from both Gram-positive and Gram-negative pathogens. Resistance to antibiotics... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.